Filtered By:
Condition: Bleeding
Procedure: Angioplasty

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 1131 results found since Jan 2013.

Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis
CONCLUSIONS: Among HBR patients implanted with new-generation DES, short DAPT was associated with reduced risk of major bleeding without significantly increasing the risk of definite or probable ST and MI in comparison with standard DAPT.PMID:35912712 | DOI:10.5603/CJ.a2022.0071
Source: Cardiology Journal - August 1, 2022 Category: Cardiology Authors: Yan Han Xiaohang Yuan Xin Hu Yan Fang Mengting Jiang Huanhuan Feng Lei Gao Source Type: research

Efficacy and Safety of De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Clinical Trials
Abstract: Considering that there is no definite conclusion on the efficacy and safety of switching from potent P2Y12 inhibitors to clopidogrel, we conducted a systematic review and meta-analysis of patients with acute coronary syndromes undergoing percutaneous coronary intervention and compared the efficacy and safety of de-escalation or not of antiplatelet therapy. The relevant randomized controlled trials were included by searching several databases. Net adverse clinical events were identified as the composite end point, which was defined as a composite of cardiovascular death, myocardial infarction, revascularizatio...
Source: Journal of Cardiovascular Pharmacology - August 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention
ConclusionsCombination of low-dose prasugrel and DOAC was associated with lower incidence of MI, ischemic stroke, and blood transfusion. Low-dose prasugrel may be feasible as part of triple therapy in patients undergoing PCI.
Source: PLoS One - July 28, 2022 Category: Biomedical Science Authors: Hideki Kitahara Source Type: research

Influence of the Danish Co-morbidity Index Score on the Treatment and Outcomes of 2.5 Million Patients Admitted With Acute Myocardial Infarction in the United States
This study aimed to determine the association between the Danish Co-morbidity Index for Acute Myocardial Infarction (DANCAMI) and restricted DANCAMI (rDANCAMI) scores and clinical outcomes in patients hospitalized with AMI. Using the National Inpatient Sample, all AMI hospitalizations were stratified into four groups based on their DANCAMI and rDANCAMI score (0; 1 to 3; 4 to 5; ≥6). The primary outcome was all-cause mortality, whereas secondary outcomes were major adverse cardiovascular/cerebrovascular events, major bleeding, ischemic stroke, and receipt of coronary angiography or percutaneous coronary intervention.
Source: The American Journal of Cardiology - July 14, 2022 Category: Cardiology Authors: Balamrit Singh Sokhal, Andrija Mateti ć, Abhishek, Philip Freeman, Jan Walter Dhillon Shanmuganathan, Mohamed O. Mohamed, Christian Mallen, Mamas A. Mamas Source Type: research

Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Abstract: Tirofiban has been used historically as a bridge to platelet inhibition with clopidogrel in ST-segment myocardial infarction (STEMI) during percutaneous coronary intervention (PCI) to prevent stent thrombosis. However, ticagrelor and prasugrel reach similar levels of platelet inhibition at 30 minutes to that of clopidogrel at 6 hours, challenging the need for long-duration tirofiban. This 1-year, retrospective cohort study compared ischemic and bleeding outcomes of short-duration versus long-duration tirofiban regimens in patients with STEMI who received ticagrelor or prasugrel at the time of PCI. The primary...
Source: Journal of Cardiovascular Pharmacology - July 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
CONCLUSION: In patients with AF, stable CAD, and preserved renal function, rivaroxaban underdose was associated with similar rates of thrombotic events but a lower incidence of hemorrhagic events than the standard dose.CLINICAL TRIAL REGISTRATION: AFIRE UMIN Clinical Trials Registry (https://www.umin.ac.jp/ctr/), number UMIN000016612, and ClinicalTrials.gov, number NCT02642419.PMID:35697255 | DOI:10.1055/s-0042-1744543
Source: Thrombosis and Haemostasis - June 13, 2022 Category: Hematology Authors: Hiroyuki Arashi Junichi Yamaguchi Nobuhisa Hagiwara Satoshi Yasuda Koichi Kaikita Masaharu Akao Junya Ako Tetsuya Matoba Masato Nakamura Katsumi Miyauchi Kazuo Kimura Atsushi Hirayama Kunihiko Matsui Hisao Ogawa Source Type: research

Comparative effectiveness and safety of different combinations of antithrombotic regimens in atrial fibrillation patients with stent insertions
This study aims to compare the risks of major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, ischemic stroke and transient ischemic attack, and major bleeding across different antithrombotic regimens in Asian atrial fibrillation (AF) patients with stent insertions. We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database and National Mortality Registry. A total of 10,208 nonvalvular AF patients who had undergone percutaneous coronary intervention (PCI) with stents for the first time in 2007-2017 were identified. Most patients (68.4%) were p...
Source: Clinical Pharmacology and Therapeutics - June 9, 2022 Category: Drugs & Pharmacology Authors: Han-Hsin Chueh Shih-Tsung Huang Shang-Hung Chang Shin-Yi Lin Fei-Yuan Hsiao Source Type: research

Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry
CONCLUSIONS: The AVIATOR 2 study is the first digital health study examining physician-patient perspectives on ATT choices after AF-PCI. TT was the most common strategy without differences in 1-year outcomes in ATT strategy. Physicians rated safety first when prescribing ATT; patients feared stroke over bleeding.CLINICALTRIALS: gov: NCT02362659.PMID:35656720 | DOI:10.4244/EIJ-D-21-01044
Source: EuroIntervention - June 3, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Jaya Chandrasekhar Usman Baber Samantha Sartori Ridhima Goel Johny Nicolas Birgit Vogel Clayton Snyder Annapoorna Kini Carlo Briguori Bernhard Witzenbichler Ioannis Iakovou Gennaro Sardella Kevin Marzo Anthony DeFranco Thomas Stuckey Alaide Chieffo Antoni Source Type: research